Islandness: Vulnerability and resilience in Oceania

John R. Campbell

PLoS ONE · 2009 · 98 citations · 1 references

DOIFull text

Open access

Concepts

Abstract

The drug development pipeline for LSDs is growing and evolving, with increased focus on diverse small-molecule targets and gene therapy. CLN2 was the first and only LSD with an approved therapy directly targeted to the brain. Newly approved products included "me-too"-enzymes and innovative compounds such as the first pharmacological chaperone for the treatment of Fabry disease.

References

1